Gland Pharma Limited - Asset Resilience Ratio

Latest as of March 2025: 3.53%

Gland Pharma Limited (GLAND) has an Asset Resilience Ratio of 3.53% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Gland Pharma Limited (GLAND) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Rs3.96 Billion

≈ $42.83 Million USD Cash + Short-term Investments

Total Assets

Rs112.25 Billion

≈ $1.21 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Gland Pharma Limited's Asset Resilience Ratio has changed over time. See Gland Pharma Limited net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Gland Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Gland Pharma Limited market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs3.96 Billion	3.53%
Total Liquid Assets	Rs3.96 Billion	3.53%

Asset Resilience Insights

Limited Liquidity: Gland Pharma Limited maintains only 3.53% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Gland Pharma Limited Industry Peers by Asset Resilience Ratio

Compare Gland Pharma Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	9.09%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.02%
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	Drug Manufacturers - Specialty & Generic	0.01%
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	Drug Manufacturers - Specialty & Generic	26.36%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%

Annual Asset Resilience Ratio for Gland Pharma Limited (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Gland Pharma Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	3.53%	Rs3.96 Billion ≈ $42.83 Million	Rs112.25 Billion ≈ $1.21 Billion	-11.31pp
2024-03-31	14.84%	Rs15.82 Billion ≈ $171.05 Million	Rs106.61 Billion ≈ $1.15 Billion	-6.29pp
2023-03-31	21.12%	Rs18.54 Billion ≈ $200.50 Million	Rs87.78 Billion ≈ $949.26 Million	-16.24pp
2022-03-31	37.36%	Rs29.27 Billion ≈ $316.53 Million	Rs78.34 Billion ≈ $847.18 Million	-1.29pp
2021-03-31	38.65%	Rs25.11 Billion ≈ $271.52 Million	Rs64.96 Billion ≈ $702.53 Million	+10.68pp
2020-03-31	27.97%	Rs11.43 Billion ≈ $123.58 Million	Rs40.86 Billion ≈ $441.89 Million	+14.22pp
2019-03-31	13.75%	Rs4.84 Billion ≈ $52.38 Million	Rs35.24 Billion ≈ $381.06 Million	+4.25pp
2018-03-31	9.50%	Rs2.78 Billion ≈ $30.10 Million	Rs29.29 Billion ≈ $316.81 Million	--

pp = percentage points

About Gland Pharma Limited

NSE:GLAND India Drug Manufacturers - Specialty & Generic

Market Cap

$3.12 Billion

Rs288.46 Billion INR

Market Cap Rank

#4815 Global

#206 in India

Share Price

Rs1750.80

Change (1 day)

+0.67%

52-Week Range

Rs1403.90 - Rs2102.10

All Time High

Rs4272.42